Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • Comparison of Haploidentical Donor Transplant versus 7/8 HLA-mismatched Unrelated Donor Allogeneic Stem Cell Transplant in Acute Myeloid Leukemia and Myelodysplastic Syndrome

    Cancer Categories
    • Hematologic (Blood Cancers)
    Karmanos Trial ID
    • 2020-131
    Age Group
    • Adult
    • Local
    PhaseClick for Clinical Trial Phase DefinitionPhase Not Applicable
    Trials without phases (for example, studies of devices or behavioral interventions)
    • NA
    Principal Investigator
    • Dipenkumar
      Modi, M.D.

      Oncology - Hematology, Oncology - Medical View Profile


    The objectives are to estimate acute GVHD (aGVHD) rate, chronic GVHD (cGVHD) rate, relapse-free survival (RFS), overall survival (OS), GVHD-free relapse-free survival (GRFS), relapse rate, and non-relapse mortality (NRM) for AML and MDS patients by HIDT and 7/8 HLA-MMUD separately.
  • Locations


    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266